New & Noteworthy

November 2018

CSTD Conforms to NIOSH Protocol

Equashield Compounding Technologies

CSTD Conforms to NIOSH Protocol

A recent study conducted by the University of North Carolina evaluated six CSTD systems on the market, using isopropyl alcohol as a surrogate for chemotherapy medication, per NIOSH’s 2015 proposed testing protocol. Equashield was found to adequately contain hazardous drug vapors and aerosols throughout the compounding and administration process. Containment of hazardous vapors is one of several factors used to assess the effectiveness of CSTDs, and use of isopropyl alcohol serves as a realistic worst case surrogate for such assessment.

Equashield LLC

Request More Information

Current Issue